GlassScriptPhysician profile
Jane Z Cai
NPI 1437164944
$4,662.80
in general payments reported to CMS, 2019-2025
32 companies · $486 in 2025
The $486 reported for 2025 was more than what 79% of Geriatric Medicine (Internal Medicine) providers received nationally (typical 2025 total: $123).
See the full distribution for Geriatric Medicine (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,458 · 2020: $891 · 2021: $244 · 2022: $497 · 2023: $591 · 2024: $495 · 2025: $486.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,573.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,572.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,340.48 | 2019-2025 | Repatha, Repatha, Otezla |
| Amarin Pharma, INC. | $467.61 | 2019-2023 | |
| Eisai INC. | $292.58 | 2021-2024 | |
| Sanofi-Aventis U.S. LLC | $271.82 | 2019 | |
| Novartis Pharmaceuticals Corporation | $198.82 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $192.97 | 2019-2022 | |
| Kowa Pharmaceuticals America, INC. | $162.80 | 2019-2022 | |
| Glaxosmithkline, LLC. | $161.48 | 2019-2023 | Arexvy, Shingrix |
| Lilly USA, LLC | $160.77 | 2020-2025 | Zepbound |
| Pfizer INC. | $152.98 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $149.09 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $142.58 | 2019 | |
| Abbott Laboratories | $134.63 | 2023 | Infinity |
| Janssen Pharmaceuticals, INC | $119.40 | 2021-2023 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $101.60 | 2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $89.50 | 2019-2021 | |
| Esperion Therapeutics, INC. | $79.83 | 2020-2024 | Nexletol |
| Sumitomo Pharma America, INC. | $67.25 | 2024 | Gemtesa |
| Boston Scientific Corporation | $39.88 | 2020 | |
| Merck Sharp & Dohme LLC | $39.64 | 2019-2025 | Capvaxive |
| Biohaven Pharmaceutical Holding Company LTD. | $37.88 | 2022 | |
| Radius Health, INC. | $34.34 | 2019-2023 | Tymlos |
| Allergan, INC. | $33.46 | 2019 | |
| Exact Sciences Corporation | $30.16 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Ge Healthcare | $25.37 | 2019 | |
| Ibsa Pharma INC. | $24.05 | 2020 | |
| Abbvie INC. | $22.26 | 2022 | |
| Sanofi Pasteur INC. | $21.11 | 2025 | |
| Seqirus USA INC | $18.69 | 2025 | Flucelvax |
| Astellas Pharma US INC | $18.35 | 2019 | |
| Nestle Healthcare Nutrition INC. | $16.58 | 2020 | |
| Life Molecular Imaging LTD | $14.84 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jane Cai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.